Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
26
27
28
29
30
31
2
3
4
5
6
7
8
9
10
8:30 AM - HIMSS Europe
11
12
13
14
15
16
17
18
19
20
21
22
26
27
28
29
1
2
3
4
5
6
e-Health 2025 Conference and Tradeshow
2025-06-01 - 2025-06-03    
10:00 am - 5:00 pm
The 2025 e-Health Conference provides an exciting opportunity to hear from your peers and engage with MEDITECH.
HIMSS Europe
2025-06-10 - 2025-06-12    
8:30 am - 5:00 pm
Transforming Healthcare in Paris From June 10-12, 2025, the HIMSS European Health Conference & Exhibition will convene in Paris to bring together Europe’s foremost health [...]
38th World Congress on  Pharmacology
2025-06-23 - 2025-06-24    
11:00 am - 4:00 pm
About the Conference Conference Series cordially invites participants from around the world to attend the 38th World Congress on Pharmacology, scheduled for June 23-24, 2025 [...]
2025 Clinical Informatics Symposium
2025-06-24 - 2025-06-25    
11:00 am - 4:00 pm
Virtual Event June 24th - 25th Explore the agenda for MEDITECH's 2025 Clinical Informatics Symposium. Embrace the future of healthcare at MEDITECH’s 2025 Clinical Informatics [...]
International Healthcare Medical Device Exhibition
2025-06-25 - 2025-06-27    
8:30 am - 5:00 pm
Japan Health will gather over 400 innovative healthcare companies from Japan and overseas, offering a unique opportunity to experience cutting-edge solutions and connect directly with [...]
Electronic Medical Records Boot Camp
2025-06-30 - 2025-07-01    
10:30 am - 5:30 pm
The Electronic Medical Records Boot Camp is a two-day intensive boot camp of seminars and hands-on analytical sessions to provide an overview of electronic health [...]
Events on 2025-06-01
Events on 2025-06-10
HIMSS Europe
10 Jun 25
France
Events on 2025-06-23
38th World Congress on  Pharmacology
23 Jun 25
Paris, France
Events on 2025-06-24
Events on 2025-06-25
International Healthcare Medical Device Exhibition
25 Jun 25
Suminoe-Ku, Osaka 559-0034
Events on 2025-06-30

Events

Articles

Nov 16: EHR Association Backs No FDA Regulation For EHR Systems

fda regulation

The Electronic Health Record Association, which represents 40 EHR developer companies whose products are in use at a majority of hospitals and physician practices today, applauds an FDA Regulation workgroup recommendation that healthcare technology, such as EHR systems, should not be treated as medical devices and should remain unregulated.

However, the group, in a Nov. 6 letter to HHS Secretary Kathleen Sebelius, asked for clarification on a number of topics, including clinical decision support, medical device accessories, reporting of safety event and post-market surveillance and “Class 0.”

“We are not convinced that most HIT not regulated as a medical device should receive a new ‘Class 0’ device classification by the FDA. Such a classification and application for a formal regulatory approach to HIT is not warranted in our view,” stated the letter signed by the EHR Association Executive Committee members, whose chair is Michele McGlynn, senior director, strategy and operations at Siemens.

The Association recommended the following:

  • Any definition of HIT used in a new risk-based policy framework should align with existing market definitions. The focus should be on what specific types of HIT are subject to which types of regulation or oversight, if any.
  •  A patient safety risk framework and examples should be used as building blocks to develop a robust and transparent plan that that would allow application of oversight by level of risk and associated costs and benefits of oversight. Any such framework must include weights for risk elements and a model to combine results.
  • To the extent that enforcement discretion is used, it should be used in a manner that creates greater predictability as opposed to regulatory uncertainty, with enforcement discretion identified as the clear outcome of a considered policy process and one that can be expected to remain in place for some time. We believe that the approach taken related to the recent FDA guidance on mobile devices is a good example of providing useful guidance and minimizing uncertainty, while allowing the framework and the market to evolve. As a general proposition, we urge that any deliberations regarding increased oversight of HIT be conducted in ways that increase predictability and certainty for developers and providers

source